Lexicon Pharmaceuticals Inc. (LXRX)

1.93
0.03 1.30
NASDAQ : Health Technology
Prev Close 1.90
Open 1.91
Day Low/High 1.88 / 1.94
52 Wk Low/High 1.12 / 6.49
Volume 599.83K
Avg Volume 914.90K
Exchange NASDAQ
Shares Outstanding 106.97M
Market Cap 204.31M
EPS 1.20
P/E Ratio 2.36
Div & Yield N.A. (N.A)

Latest News

4 Smaller Biotech Names Worth Researching

4 Smaller Biotech Names Worth Researching

Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Cutting Through the Fed Confusion

So where does the market go from here?

Sneaky Market Strength Has Nothing to Do With the Fed

Anxiety over being left behind is building.

Yawning All the Way to the Fed Decision

We have a few more days of this slow trading, and it is unlikely to change much.

Ugly Friday Finishes Off Last Week's Hope

Signs of support on the S&P, but there is a lot of uncertainty.

When and Where Will We Find a Bottom?

When and Where Will We Find a Bottom?

Market is following textbook corrective action.

Minor Selling Was Exactly What Was Needed

Minor Selling Was Exactly What Was Needed

But bears finally have some momentum heading into a seasonally poor month.

Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade

Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade

Lexicon Pharmaceuticals (LXRX) shares are up nearly 50% since it announced Monday that its carcinoid syndrome drug telotristat etiprate met its primary endpoint in a late stage clinical trial.

Market Wrap: Stocks Fall With Price of Oil

Market Wrap: Stocks Fall With Price of Oil

Energy and materials names lead the losers.